Skip to content

US · DVA · MEDICAL - CARE FACILITIES

DaVita Inc. (DVA) intrinsic value and stock valuation

$161.03as of 2026-11-21 · Mkt cap 12.11B

Data updated · price as of 2026-11-21

Fairly valuedIC value is within 20% of the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

DaVita Inc. DCF and intrinsic value

InvestorsCraft values DVA with the Chepakovich two-stage DCF model — currently rated fairly valued. How the model works · Run your own DCF prefilled from DVA’s statements →

DaVita Inc. Graham Number

Graham Number: $51.24d — the price is above the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →

Healthcare · Medical - Care Facilities Denver, CO 80202 davita.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$13.6B+3.4% 5y CAGRd
20112025
Net income
$746.8M-0.7% 5y CAGRd
20112025
Free cash flow
$1.31B+0.1% 5y CAGRd
20112025
Total equity
$1.16B-16.7% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$13.6B$12.8B$12.1B$11.6B$11.6B
Operating income$2.01B$2.09B$1.6B$1.34B$1.8B
Net income$746.8M$936.3M$691.5M$560.4M$978.5M
EPSd$8.48M$10.7M$7.42M$5.85M$8.9M
Operating cash flow$1.89B$2.02B$2.06B$1.56B$1.93B
Capital expenditure-$-575.86M-$-555.44M-$-567.99M-$-603.43M-$-641.47M
Free cash flow$1.31B$1.47B$1.49B$961.1M$1.29B
Total assets$17.5B$17.3B$16.9B$16.9B$17.1B
Total debt$15B$12.1B$11.1B$11.8B$12B
Net debt$14.3B$11.3B$10.7B$11.6B$11.5B
Total equity$1.16B$2.09B$2.74B$2.22B$2.37B
Cash and short-term investments$782.1M$846M$391.7M$321.8M$484.2M
Income statement
20252024202320222021
Revenue$13.6B$12.8B$12.1B$11.6B$11.6B
Cost of revenue$9.96B$8.6B$8.32B$8.21B$7.97B
Gross profit$3.68B$4.22B$3.82B$3.4B$3.65B
Research and development expenses$0.00$0.00$0.00$0.00$0.00
Selling, general and administrative expenses$1.67B$1.54B$1.47B$1.36B$1.2B
Other expenses$0.00$588.2M$743.7M$706.1M$653.7M
Operating expenses$1.67B$2.13B$2.22B$2.06B$1.85B
Cost and expenses$11.6B$10.7B$10.5B$10.3B$9.82B
Interest income$0.00$0.00$0.00$0.00$0.00
Interest expense$549.7M$470.5M$398.6M$357M$285.3M
Depreciation and amortization$715.4M$723.9M$745.4M$732.6M$680.6M
Ebitda$2.64B$2.72B$2.32B$2.06B$2.48B
Operating income$2.01B$2.09B$1.6B$1.34B$1.8B
Total other income/expenses, net-$-663.79M-$-560.09M-$-425.69M-$-372.78M-$-278.88M
Income before tax$1.35B$1.53B$1.18B$966.3M$1.52B
Income tax expense$293.1M$279.7M$220.1M$198.1M$306.7M
Net income$746.8M$936.3M$691.5M$560.4M$978.5M
Weighted average shares outstanding$86.1M$85M$90.8M$93M$105.2M
Weighted average diluted shares outstanding$88.1M$87.3M$93.2M$95.8M$110M
Balance sheet
20252024202320222021
Cash and short-term investments$782.1M$846M$391.7M$321.8M$484.2M
Net receivables$2.96B$2.56B$2.42B$2.55B$2.41B
Inventory$160.6M$134.6M$143.1M$109.1M$107.4M
Total current assets$4.06B$3.75B$3.14B$3.16B$3.17B
Property, plant and equipment, net$5.21B$5.33B$5.57B$5.92B$6.3B
Goodwill and intangible assets$7.77B$7.57B$7.32B$7.26B$7.22B
Long-term investments$198.2M$370.3M$593.7M$275.4M$288.4M
Total non-current assets$13.4B$13.5B$13.8B$13.8B$14B
Total assets$17.5B$17.3B$16.9B$16.9B$17.1B
Accounts payable$696.2M$547.2M$514.5M$479.8M$402.1M
Short-term debt$534.7M$681.3M$517.7M$626.8M$573.4M
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$3.14B$2.97B$2.64B$2.62B$2.4B
Long-term debt$14.5B$11.4B$10.6B$11.2B$11.4B
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$13.2B$12.2B$11.5B$12.1B$12.4B
Capital lease obligations$2.6B$2.62B$2.72B$2.9B$3.07B
Total liabilities$16.3B$15.2B$14.2B$14.7B$14.8B
Common stock$70K$90K$90K$90K$100K
Retained earnings-$-328.43M$1.53B$598.3M$174.5M$354.3M
Accumulated other comprehensive income (loss)-$-122.78M-$-310.8M-$-52.08M-$-69.19M-$-139.25M
Total equity$1.16B$2.09B$2.74B$2.22B$2.37B
Total investments$222.5M$421.4M$605.4M$353.1M$310.7M
Total debt$15B$12.1B$11.1B$11.8B$12B
Net debt$14.3B$11.3B$10.7B$11.6B$11.5B
Cash flow statement
20252024202320222021
Net income$1.08B$1.25B$691.5M$781.6M$1.21B
Depreciation and amortization$715.4M$723.9M$745.4M$732.6M$680.6M
Stock-based compensation$140M$102.8M$112.4M$95.4M$102.2M
Change in working capital-$-263.24M-$-29.82M$194.5M$100K-$-140.64M
Accounts receivable-$-210.63M-$-29.77M$172.4M-$-148.39M-$-138.14M
Inventory-$-19.95M$17.9M-$-32.13M-$-760K$5.72M
Accounts payable$128.3M$1.7M$26.9M$87.5M-$-30.32M
Net cash provided by operating activities$1.89B$2.02B$2.06B$1.56B$1.93B
Investments in property, plant and equipment-$-575.86M-$-555.44M-$-567.99M-$-603.43M-$-641.47M
Acquisitions, net-$-144.5M-$-251.27M-$-26.39M-$-89.19M-$-200.97M
Net cash used for investing activities-$-654.95M-$-771.43M-$-771.8M-$-630.35M-$-784.73M
Common stock issued$23.3M$20.5M$16.9M$18.6M$0.00
Common stock repurchased-$-1.79B-$-1.39B-$-272.22M-$-802.23M-$-1.6B
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities-$-1.37B-$-816.94M-$-1.17B-$-1.12B-$-1.08B
Net change in cash-$-122.08M$415.2M$125.6M-$-215.97M$53.2M
Cash at end of period$757.8M$879.8M$464.6M$339M$555M
Operating cash flow$1.89B$2.02B$2.06B$1.56B$1.93B
Capital expenditure-$-575.86M-$-555.44M-$-567.99M-$-603.43M-$-641.47M
Free cash flow$1.31B$1.47B$1.49B$961.1M$1.29B
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About DaVita Inc.

        DaVita Inc. specializes in delivering essential kidney dialysis treatments and comprehensive renal care to individuals grappling with chronic kidney failure. The company primarily operates an extensive network of outpatient dialysis centers, supplementing this with services provided in hospital inpatient settings and within patients' homes. Beyond direct patient treatment, DaVita manages its own diagnostic laboratories, performing routine tests vital for dialysis patients, alongside other physician-ordered laboratory analyses specifically for those with end-stage renal disease (ESRD). The firm also offers administrative and management support to various other outpatient dialysis facilities. Its broad spectrum of offerings extends to chronic disease management programs, supporting a substantial patient cohort; by year-end 2021, this included 16,000 patients enrolled in risk-based integrated care models and an additional 7,000 in other integrated care arrangements. Further specialized services encompass vascular access interventions, clinical research initiatives, direct physician support, and a complete suite of holistic kidney care solutions. As of December 31, 2021, DaVita's footprint across the United States comprised 2,815 outpatient dialysis centers, collectively serving approximately 203,100 patients. Globally, the company operated 339 outpatient dialysis centers spread across ten countries outside the U.S., attending to roughly 39,900 patients. Moreover, it furnished acute inpatient dialysis services and related laboratory work in around 850 U.S. hospitals. Founded in 1994, DaVita Inc. maintains its headquarters in Denver, Colorado. The company rebranded to its current name in September 2016, having previously been known as DaVita HealthCare Partners Inc.

        CEO
        Javier J. Rodriguez
        Employees
        78K
        Beta
        0.88

        Included in

        Explore

        Frequently asked questions

        What is the intrinsic value of DaVita Inc. (DVA)?

        DaVita Inc. (DVA) is currently fairly valued based on the InvestorsCraft IC model — IC value is within 20% of the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is DVA undervalued?

        DVA trades at a price of $161.03 (Nov 21, 2026): fairly valued — IC value is within 20% of the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.